WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 525315
CAS#: 669076-03-3
Description: JNJ-26076713 is an orally active alpha V integrin antagonist. JNJ-26076713 represents a potential therapeutic candidate for the treatment of age-related macular degeneration, macular edema, and proliferative diabetic retinopathy.
MedKoo Cat#: 525315
Name: JNJ-26076713
CAS#: 669076-03-3
Chemical Formula: C29H38N4O3
Exact Mass: 490.29439
Molecular Weight: 490.64
Elemental Analysis: C, 70.99; H, 7.81; N, 11.42; O, 9.78
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: JNJ-26076713; JNJ26076713; JNJ 26076713.
IUPAC/Chemical Name: 3-Quinolinepropanoic acid, 1,2,3,4-tetrahydro-beta-((1-(1-oxo-3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl)-4-piperidinyl)methyl)-, (betaS,3S)-
InChi Key: AJVBWPQQXWRZHQ-BJKOFHAPSA-N
InChi Code: InChI=1S/C29H38N4O3/c34-27(10-9-25-8-7-21-5-3-13-30-29(21)32-25)33-14-11-20(12-15-33)16-23(18-28(35)36)24-17-22-4-1-2-6-26(22)31-19-24/h1-2,4,6-8,20,23-24,31H,3,5,9-19H2,(H,30,32)(H,35,36)/t23-,24+/m0/s1
SMILES Code: O=C(O)C[C@H](CC1CCN(C(CCC2=CC=C3CCCN=C3N2)=O)CC1)[C@H]4CNC5=C(C=CC=C5)C4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 490.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Kinney WA, Teleha CA, Thompson AS, Newport M, Hansen R, Ballentine S, Ghosh S, Mahan A, Grasa G, Zanotti-Gerosa A, Dingenen J, Schubert C, Zhou Y, Leo GC, McComsey DF, Santulli RJ, Maryanoff BE. Suzuki-Miyaura approach to JNJ-26076713, an orally active tetrahydroquinoline-containing alphaVbeta3/alphaVbeta5 integrin antagonist. enantioselective synthesis and stereochemical studies. J Org Chem. 2008 Mar 21;73(6):2302-10. doi: 10.1021/jo702551t. Epub 2008 Feb 16. PubMed PMID: 18278942.
2: Santulli RJ, Kinney WA, Ghosh S, Decorte BL, Liu L, Tuman RW, Zhou Z, Huebert N, Bursell SE, Clermont AC, Grant MB, Shaw LC, Mousa SA, Galemmo RA Jr, Johnson DL, Maryanoff BE, Damiano BP. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. J Pharmacol Exp Ther. 2008 Mar;324(3):894-901. Epub 2007 Dec 14. PubMed PMID: 18083913.